<DOC>
	<DOCNO>NCT02647515</DOCNO>
	<brief_summary>To determine efficacy intravitreal ranibizumab injection adjuvant therapy treatment postvitrectomy diabetic vitreous hemorrhage ( PDVH ) accompany neovascular glaucoma ( NVG ) mean prevent recurrent vitreous hemorrhage （VH） optimize postoperative intraocular pressure（IOP）control .</brief_summary>
	<brief_title>Intravitreal Ranibizumab Injection Adjuvant Treatment Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied Neovascular Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>age≥18 year PDVH obscure disc vessel 14 day evidence retinal detachment primary vitrectomy PDRrelated complication nonclearing VH , maculainvolving maculathreatening tractional retinal detachment , fibrovascular proliferation vitreoretinal adhesion NVG occur follow PDVH le 4 week ( NVG diagnose IOP elevation 22mmHg accompany neovascularization iris and/or anterior chamber angle ) intraoperative use longacting gas silicone oil primary vitrectomy , repeat vitrectomy primary vitrectomy retinal disease VH , previous history vitrectomy previous intravitreal injection ranibizumab bevacizumab either eye previous intravitreal corticosteroid injection either eye pregnancy current oral contraceptive intake usage clopidogrel bisulfate coumadin uncontrolled hypertension cardiac disease uncontrolled renal liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>